Testing a novel peptide drug towards a goal of reducing mortality in critically ill COVID19 patients
- Sandia National Lab. (SNL-CA), Livermore, CA (United States)
COVID 19 has been devastating the globe over the past year, and although our knowledge of how the disease progresses is constantly evolving, there is a significant amount we now about the mechanisms underlying COVID19. There is growing evidence that a 'cytokine storm' is a significant driver of mortality associated with COVID19, with studies showing high levels of hallmark inflammatory indicators in critically ill COVID19 patients. This essentially consists of the patient's immune system going awry and causing white blood cells to constantly release a large number of small molecules called cytokines. The result of this is further activation of the immune system, which ends up attacking not only infected but also healthy patient tissues, resulting in organ failure.
- Research Organization:
- Sandia National Laboratories (SNL-CA), Livermore, CA (United States)
- Sponsoring Organization:
- USDOE National Nuclear Security Administration (NNSA); USDOE Laboratory Directed Research and Development (LDRD) Program
- OSTI ID:
- 1673818
- Report Number(s):
- SAND--2020-10382; 691384
- Country of Publication:
- United States
- Language:
- English
Similar Records
Immediate intralipid clearance from plasma in critically ill patients after a single-dose injection